By employing a multifaceted approach that includes pan‐cancer expression analysis, evaluation of subcellular localization, functional assays in HCC cell lines and assessments of the immune microenvironment and drug sensitivity, we seek to delineate the role of FAM210B in HCC progression and therapeutic selection. Here, MIMS2 is linked to hepatocellular carcinoma.